Inaugural 'Tianhai Cup' Cell and Gene Therapy Innovation and Entrepreneurship Competition Launched

In recent years, the cell and gene therapy (CGT) industry has experienced rapid growth, addressing unmet clinical needs and offering hope for curing genetic disorders, malignant tumors, refractory chronic diseases, and infectious diseases. National and local governments have intensively rolled out supportive policies to bolster the development of the CGT sector. Currently, 19 CGT products have been approved for commercial sale worldwide. In 2021, two CAR-T products received marketing approval in China, and multiple cell and gene therapy products have obtained implicit clinical trial approvals. The CGT industry in China has set sail and is poised to enter its golden age.

The inaugural “Tianhai Cup” Cell and Gene Therapy Innovation and Entrepreneurship Competition has officially kicked off, with registration now in full swing. Focused on the biopharmaceutical sector, the competition highlights innovative R&D achievements in cell and gene therapy (CGT), emphasizes technological and service innovation, and actively promotes the translation and commercialization of innovative outcomes. Distinguished industry experts, scholars, leading entrepreneurs, and investors will serve as judges, providing high-quality projects with opportunities for collaboration, exchange, and financing.

This competition is jointly hosted by the Haihe Laboratory of Cell Ecosystem, the Institute of Hematology & Blood Diseases Hospital (Institute of Hematology) of the Chinese Academy of Medical Sciences, the Tianjin Institute of Health and Medicine of the Chinese Academy of Medical Sciences, and the Administrative Committee of Tianjin Binhai High-Tech Industrial Development Zone.Pool efforts to bridge the “last mile” in translating research findings into practical applications, contributing to the high-quality development of the biopharmaceutical industry.

Host:Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital (Institute of Hematology, Chinese Academy of Medical Sciences), Tianjin Institute of Health and Medicine of the Chinese Academy of Medical Sciences, and Administrative Committee of Tianjin Binhai High-Tech Industrial Development Zone

Organizer:Tianhai Future (Tianjin) Biotechnology Co., Ltd.

Co-organizers:bioSeedin, Vcanbio, Haier Venture Capital, ACROBiosystems, Haihe Fund

(1) Scope of Competition Entries: CGT innovative drugs, key equipment in the CGT industry chain, raw and auxiliary materials and packaging materials, and innovative technology service platforms

(2) Entrepreneurial teams with technological innovation achievements and business plans in the field of Cell and Gene Therapy (CGT), with no fewer than three core team members

(3) The products and technologies of the participating projects have clear intellectual property rights and are free from any ownership disputes.

Call for Projects:From now until October 20, 2022

Final Roadshow:Mid-November 2022, Tianjin

Bonus Rewards:First Prize: 200,000 yuan; Second Prize: 150,000 yuan; Third Prize: 50,000 yuan

Policy Support:CGT Industry Incubation, Talent Services, Infrastructure Support, and Green Channel for Intellectual Property Approval

Resource Matching:Upstream and downstream industry players, hospital clinical resources, and investment institutions

Brand Promotion:In-depth exchanges with government officials, industry peers, investment firms, and potential partners at the conference; opportunities for exclusive team interviews

Please send the business plan (BP) or complete the competition registration form (choose one) toxbstcgzh@ihcams.ac.cn, with the email subject line titled “CGT Innovation and Entrepreneurship Competition + Project Name”

After review by the Evaluation Committee, the final shortlisted projects will be notified via phone and email at the earliest opportunity.

Inquiry Hotline

Teacher Si, Teacher Li

022-23909383

Scan the QR code to download registration materials